Kicking them off Wegovy and Zepbound now, she argues, would reverse the progress already made: All that money you just put in, youre going to throw away. Around the country, however, other insurers faced with the same costs as PEIA have been largely unswayed by the argument that covering obesity drugs will ultimately save money, by preventing obesity-related conditions such as diabetes and heart attacks down the line
Research shows that tirzepatide reduces food preference scores in multiple food categories, particularly for energy-dense options, while preferences for fruits and vegetables tend to remain unchanged
KLOW is not appropriate for patients who are pregnant or breastfeeding, have active cancer or a recent cancer history, or are on immunosuppressive therapy
(2005) Incretin mimetics as emerging treatments for type 2 diabetes
But those trials havent yet been completed for opioid use disorder specifically